Abstract:
Rabies is a worldwide problem, and the case is most severe in developing countries where cell culture anti-rabiesvaccines are unaffordable or the available nervous tissue-derived vaccines are of questionable immunogenicity andmay cause neurological complications. The aim of this research was to study cross protection of local rabies virusisolates with Evenyl Roktincki Abelseth (ERA) based cell culture anti-rabies vaccine produced in Ethiopia and todevelop challenge virus from local isolates. The viruses were isolated from rabid dogs’ brains and human saliva, andadapted on Swiss albino mice and cell lines. Cross protection with ERA based vaccine was studied by in vivo and invitro methods. For in vivo method, a group of mice were immunized on day zero and seven with 0.5 ml (1:5 dilutions)of ERA based cell culture anti-rabies vaccine produced locally. On day fourteenth, mice were challenged withworking dilution of each local isolates and one group with challenge virus standard (CVS-11), and observed for further 14 days. High protection was recorded in CVS-11 challenged mice and low protection in all local isolates(p=0.045); specifically protection to HOS challenged mice was very low. In vitro test was done by fluorescentantibody virus neutralization (FAVN) test on BHK-21 cell lines. Sera from dog immunized with locally producedvaccine and OIE serum were incubated with local virus isolates and CVS-11 for 48 hours in the presence of celllines. Maximum antibody titer (2.74 IU/ml) was obtained with CVS-11 challenge virus and minimum antibody titer (1.55 IU/ml) was obtained with cow origin (CO) virus isolate. All locally isolated rabies virus show low antibody titer when compared to CVS-11 and PV-12 (p=0.000). From the results, it can be concluded that local isolates havesome genetic variation from fixed virus strain which can affect efficacy of the candidate vaccine and potency valueshould be set in-terms of local isolate using as challenge virus. Generally, the exact genetic relationship should bestudied by molecular techniques and locally isolated virus should be used as challenge virus for vaccine qualitycontro.
